Please login to the form below

Not currently logged in
Email:
Password:

Exjade

This page shows the latest Exjade news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

The committee also recommended a new generic from Mylan of Novartis’ Exjade (deferasirox), which is used to treat chronic iron overload due to blood transfusions in patients with beta thalassaemia, ... Exjade made sales of more than $1bn last year. The

Latest news

  • Novartis close to US bribery settlement Novartis close to US bribery settlement

    In 2015, Novartis paid $390m to settle claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.

  • Novartis kicks back against US corruption charges Novartis kicks back against US corruption charges

    Last November, the company settled civil claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.

  • Biogen Idec taps Sangamo for blood disorder drugs Biogen Idec taps Sangamo for blood disorder drugs

    Meanwhile, supportive therapies are also available, notably Novartis' Exjade (deferasirox) which was approved in the EU last year to manage iron overload in thalassaemia.

  • Novartis' Exjade gets EU approval for thalassaemia Novartis' Exjade gets EU approval for thalassaemia

    For the first time, Exjade will be available to thalassemia patients who are not regularly transfused but still suffer from the life-altering effects of excess iron," he added. ... Approval in thalassaemia adds to the peak sales potential for Exjade and

  • Novartis' net income up 15 per cent for Q2

    Successful launches included Exjade (deferasirox), which made $192m after receiving regulatory approvals in the US and Europe for the treatment of chronic iron overload, and Certican/Zortress (everolimus) which made $26m

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics